alpha-Pyrrolidinononanophenone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
alpha-Pyrrolidinononanophenone
Accession Number
DB05531
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • alpha-Pnp
  • alpha-Pyrrolidinononanophenone
External IDs
PV-10
Categories
Not Available
UNII
S3FKL8RY1D
CAS number
13415-58-2
Weight
Average: 287.447
Monoisotopic: 287.224914558
Chemical Formula
C19H29NO
InChI Key
RYJXAZXFWIWTOJ-UHFFFAOYSA-N
InChI
InChI=1S/C19H29NO/c1-2-3-4-5-9-14-18(20-15-10-11-16-20)19(21)17-12-7-6-8-13-17/h6-8,12-13,18H,2-5,9-11,14-16H2,1H3
IUPAC Name
1-phenyl-2-(pyrrolidin-1-yl)nonan-1-one
SMILES
CCCCCCCC(N1CCCC1)C(=O)C1=CC=CC=C1

Pharmacology

Indication

Investigated for use/treatment in actinic keratosis, breast cancer, liver cancer, melanoma, psoriasis and psoriatic disorders, and solid tumors.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
59713400
Wikipedia
PV-10

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentCancer, Breast1
1CompletedTreatmentMelanoma2
1RecruitingTreatmentCancer Metastatic to the Liver / Hepatocellular Carcinoma That is Not Amenable to Resection, Transplant or Other Potentially Curative / Hepatocellular,Carcinoma / Metastatic Breast Cancer (MBC) / Metastatic Colon Cancer / Metastatic Colorectal Cancers / Metastatic Lung Cancer / Metastatic Melanoma / Metastatic Ocular Melanoma / Metastatic Uveal Melanoma / Pancreatic Cancer Metastatic / Therapies1
1RecruitingTreatmentNeuroendocrine Tumors Metastatic to the Liver1
1, 2RecruitingTreatmentMelanoma1
2CompletedTreatmentMelanoma1
3Active Not RecruitingTreatmentCutaneous Melanoma / Recurrent Melanoma1
Not AvailableNo Longer AvailableNot AvailableApproved Alternative Therapy / Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00492 mg/mLALOGPS
logP5.25ALOGPS
logP5.14ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)17.87ChemAxon
pKa (Strongest Basic)7.81ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area20.31 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity89.45 m3·mol-1ChemAxon
Polarizability35.41 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on November 18, 2007 11:25 / Updated on June 04, 2019 06:18